Biology of Blood and Marrow Transplantation
Volume 16, Issue 2 , Pages 231-238 , February 2010

Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors: The Japan Marrow Donor Program

  • Hideki Muramatsu

      Affiliations

    • Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
    • ,
  • Seiji Kojima

      Affiliations

    • Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
    • ,
  • Ayami Yoshimi

      Affiliations

    • Department of Hematopoietic Stem Cell Transplantation Data Management, Nagoya University School of Medicine, Nagoya, Japan
    • ,
  • Yoshiko Atsuta

      Affiliations

    • Department of Hematopoietic Stem Cell Transplantation Data Management, Nagoya University School of Medicine, Nagoya, Japan
    • ,
  • Koji Kato

      Affiliations

    • Division of Pediatric Hematology/Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
    • ,
  • Yoshihisa Nagatoshi

      Affiliations

    • Section of Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan
    • ,
  • Masami Inoue

      Affiliations

    • Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan
    • ,
  • Kazutoshi Koike

      Affiliations

    • Department of Pediatrics, Ibaraki Children's Hospital, Ibaraki, Japan
    • ,
  • Takakazu Kawase

      Affiliations

    • Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
    • ,
  • Masaki Ito

      Affiliations

    • Department of Pediatrics, Fukushima Medical University School of Medicine, Fukushima, Japan
    • ,
  • Hidemitsu Kurosawa

      Affiliations

    • Department of Pediatrics, Dokkyo Medical University, Tokyo, Japan
    • ,
  • Akihiko Tanizawa

      Affiliations

    • Department of Pediatrics, University of Fukui Faculty of Medical Sciences, Fukui, Japan
    • ,
  • Chikako Tono

      Affiliations

    • Department of Pediatrics, Aomori Rosai Hospital, Aomori, Japan
    • ,
  • Kazuko Hamamoto

      Affiliations

    • Department of Pediatrics, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan
    • ,
  • Noriko Hotta

      Affiliations

    • Department of Pediatrics, Tokuyama Central Hospital, Tokuyama, Japan
    • ,
  • Akihiro Watanabe

      Affiliations

    • Department of Pediatrics, Niigata Cancer Center Hospital, Niigata, Japan
    • ,
  • Yasuo Morishima

      Affiliations

    • Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
    • ,
  • Keisei Kawa

      Affiliations

    • Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan
    • ,
  • Hiroyuki Shimada

      Affiliations

    • Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
    • Corresponding Author InformationCorrespondence and reprint requests: Hiroyuki Shimada, MD, PhD, Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan.

Received 18 July 2009 ,Accepted 24 September 2009.

References 

  1. Altman AJ. Chronic leukemias of childhood. Pediatr Clin North Am. 1988;35:765–787
  2. Creutzig U, Ritter J, Zimmermann M, Klingebiel T. Prognosis of children with chronic myeloid leukemia: a retrospective analysis of 75 patients. Klinische Padiatr. 1996;208:236–241(in German)
  3. Millot F, Esperou H, Bordigoni P, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow TransPlant. 2003;32:993–999
  4. Cwynarski K, Roberts IA, Iacobelli S, et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;102:1224–1231
  5. Gamis AS, Haake R, McGlave P, et al. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. J Clin Oncol. 1993;11:834–838
  6. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–1820
  7. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037
  8. Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006;91:513–521
  9. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58–60
  10. Guastafierro S, Falcone U, Celentano M, et al. Is it possible to discontinue imatinib mesylate therapy in chronic myeloid leukemia patients with undetectable BCR/ABL? A case report and a review of the literature. Leuk Res. 2009;33:1079–1081
  11. Speck B, Bortin MM, Champlin R, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Lancet. 1984;1:665–668
  12. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. TransPlantation. 1974;18:295–304
  13. Storb R, Prentice RL, Thomas ED. Marrow transplantation for treatment of aplastic anemia: an analysis of factors associated with graft rejection. N Engl J Med. 1977;296:61–66
  14. Dominietto A, Lamparelli T, Raiola AM, et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood. 2002;100:3930–3934
  15. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood. 1997;89:4226–4235
  16. Gengozian N, Makinodan T. Mortality of mice as affected by variation of the x-ray dose and number of nucleated rat bone marrow cells injected. Cancer Res. 1957;17:970–975
  17. Uharek L, Gassmann W, Glass B, et al. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood. 1992;79:1612–1621
  18. Pocock C, Szydlo R, Davis J, et al. Stem cell transplantation for chronic myeloid leukaemia: the role of infused marrow cell dose. Hematol J. 2001;2:265–272
  19. Maywald O, Pfirrmann M, Berger U, et al. Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia. Leukemia. 2006;20:477–484
  20. Weisser M, Schleuning M, Haferlach C, et al. Allogeneic stem cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk LymPhoma. 2007;48:295–301
  21. Lee SJ, Kukreja M, Wang T, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008;112:3500–3507
  22. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome–positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004;104:2655–2660
  23. Millot F, Guilhot J, Nelken B, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia. 2006;20:187–192
  24. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417
  25. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022–4028
  26. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496–3499
  27. Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol. 2009;89:251–252

 Financial disclosure: See Acknowledgments on page 237.

PII: S1083-8791(09)00445-5

doi: 10.1016/j.bbmt.2009.09.022

Biology of Blood and Marrow Transplantation
Volume 16, Issue 2 , Pages 231-238 , February 2010

Article Tools

* Image Usage & Resolution